Develops engineered, ready-to-use cell therapy candidates for people with diabetes, other autoimmune diseases and cancer.
10-K for FY2025, filed Mar 12, 2026
Partners pay upfront fees and may reimburse costs or pay option fees, development and regulatory milestones, sales milestones, and royalties. Research-service revenue in the Bristol-Myers Squibb collaboration is earned as Century provides the work.
10-K for FY2025, filed Mar 12, 2026The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and…View ↗
Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100,000 and agreed to…View ↗
Research and development services: The Company recognized the portion of the transaction price allocated to each of the research and…View ↗
$109.2M
10-K for FY2025, filed Mar 12, 2026
$109.2M ↗
Bristol-Myers Squibb collaborates directly with Century on cell-therapy research and development and can choose to license development candidates for further development and commercialization.
10-K for FY2025, filed Mar 12, 2026
No. It lost $9.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$23.5MView ↗
Broader disease focus
The older report framed the pipeline around cancers and malignancies, while the latest adds beta-islet therapy for diabetes and programs for other autoimmune diseases alongside cancer.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 12, 2026
Competes with Gilead Sciences, Novartis, Bristol-Myers Squibb, Adicet Bio, Allogene Therapeutics, Artiva Biotherapeutics, Caribou Biosciences, Fate Therapeutics, Nkarta Therapeutics, Cabaletta Bio, Cartesian Therapeutics, Kyverna Therapeutics, Vertex Pharmaceuticals, Sana Biotechnology, CRISPR Therapeutics, CellTrans, Sernova, GentiBio, Encelin, and Seraxis
10-K for FY2025, filed Mar 12, 2026Companies that compete with us directly on the level of the development of product candidates targeting B-cell lymphomas include but are…View ↗
Loading...